NCT06790394 - Test-retest Study With [18F]FBB in Cardiac Amyloidosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Cardiac Amyloidosis

Interventions

DRUG

Florbetaben F18

Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq).

Trial Locations (2)

NW3 2QG

Royal Free Hospital, London

SE1 7EH

King's College London, London